Literature DB >> 11054716

Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients.

W J de Leeuw1, J Dierssen, H F Vasen, J T Wijnen, G G Kenter, H Meijers-Heijboer, A Brocker-Vriends, A Stormorken, P Moller, F Menko, C J Cornelisse, H Morreau.   

Abstract

Instability of microsatellite repeat sequences has been observed in colorectal carcinomas and in extracolonic malignancies, predominantly endometrial tumours, occurring in the context of hereditary non-polyposis colorectal cancer (HNPCC). Microsatellite instability (MSI) as a feature of human DNA mismatch repair (MMR)-driven tumourigenesis of the uterine mucosa has been studied primarily in sporadic tumours showing predominantly somatic hypermethylation of MLH1. The present study shows that all endometrial carcinomas (n=12) from carriers of MLH1 and MSH2 germline mutations demonstrate an MSI-high phenotype involving all types of repeat markers, while in endometrial carcinomas from MSH6 mutation carriers, only 36% (4 out of 11) demonstrate an MSI-high phenotype. Interestingly, an MSI-high phenotype was found in endometrial hyperplasias from MSH2 mutation carriers, in contrast to hyperplasias from MLH1 mutation carriers, which exhibited an MSI-stable phenotype. Instability of only mononucleotide repeat markers was found in both endometrial carcinomas and hyperplasias from MSH6 mutation carriers. In 29 out of 31 (94%) endometrial tumour foci, combined MSI and immunohistochemical analysis of MLH1, MSH2, and MSH6 could predict the identified germline mutation. The observation of MSI in endometrial hyperplasia and of altered protein staining for the MMR genes supports the idea that inactivation of MMR genes is an early event in endometrial tumourigenesis. A correlation was found between the variation in the extent and level of MSI and the age of onset of carcinoma, suggesting differences in the rate of tumour progression. A high frequency of MSI in hyperplasias, found only in MSH2 mutation carriers, might indicate a more rapid tumour progression, correlating with an earlier age of onset of carcinoma. The present study indicates that assessment of altered protein staining combined with MSI analysis of endometrial tumours might direct the mutational analysis of MMR genes. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 11054716     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO;2-2

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  33 in total

1.  De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.

Authors:  Ajay Goel; Thuy-Phuong Nguyen; Hon-Chiu E Leung; Takeshi Nagasaka; Jennifer Rhees; Erin Hotchkiss; Mildred Arnold; Pia Banerji; Minoru Koi; Chau-To Kwok; Deborah Packham; Lara Lipton; C Richard Boland; Robyn L Ward; Megan P Hitchins
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 2.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 3.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

Review 4.  The roles of pathology in targeted therapy of women with gynecologic cancers.

Authors:  Rajmohan Murali; Rachel N Grisham; Robert A Soslow
Journal:  Gynecol Oncol       Date:  2017-11-23       Impact factor: 5.482

Review 5.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

6.  Low prevalence of germline hMSH6 mutations in colorectal cancer families from Spain.

Authors:  Ana Sánchez de Abajo; Miguel de la Hoya; Alicia Tosar; Javier Godino; Juan-Manuel Fernández; Jose-Lopez Asenjo; Beatriz-Perez Villamil; Pedro-Perez Segura; Eduardo Diaz-Rubio; Trinidad Caldes
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

7.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

8.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.

Authors:  Amanda S Bruegl; Kari L Ring; Molly Daniels; Bryan M Fellman; Diana L Urbauer; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-13

10.  MUTYH Mutations Do Not Cause HNPCC or Late Onset Familial Colorectal Cancer.

Authors:  Astrid Stormorken; Karen-Marie Heintz; Per Arne Andresen; Eivind Hovig; Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2006-05-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.